Melanotan I weist Strukturmodifikationen auf, die die Resistenz gegenber enzymatischem Abbau verbessern
For example, niches may be created by addressing specific unmet needs in certain patient types (e.g., patients who prefer not to inject, or who failed prior lines of GLP-1s), or by addressing specific access issues (e.g., developing a lower-cost option, securing broader payer coverage)
Sato, M., Muragaki, Y., Saika, S., Roberts, A
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show substantial efficacy in regulating blood glucose levels and lipid metabolism, initially as an effective treatment for diabetes mellitus
H.NielsenT.PedersenO